News

Legacy Patients From High-Dose Opioid Era

Modern pain management began to accelerate in the mid 1990’s when the fentanyl patch and extended-release oxycodone were developed and made commercially available. more info

Fentanyl Patches Overused in Vulnerable Populations

Study finds fentanyl transdermal patches are too often prescribed to opioid-naïve and elderly patients, raising their risks of fatal adverse drug events. more info

Genetic Testing in Pain Medicine—The Future Is Coming

Targeted pain therapies and screening for personality traits that may influence pain perception and addiction risk are just some of the potential promises of genetic testing in pain management. more info

DEA Ratchets Down Opioid Production

The supply of almost every Schedule II opioid manufactured in the United States will be reduced 25% or more in 2017, as required by the Drug Enforcement Administration (DEA). more info

Defining Palliative Care

Palliative care focuses on maximizing the quality of life of seriously ill patients and their families. more info

Opioid-Induced Constipation: New and Emerging Therapies—Update 2016

There has been much focus in pain management on preventing the dangerous and bothersome complications of opioid therapy, including opioid-induced constipation (OIC). more info

FDA Approves ER Hydrocodone With Abuse Deterrence Technology

The FDA has approved Vantrela ER (hydrocodone bitartrate, Teva) extended-release tablets [CII] with Teva’s proprietary abuse deterrence technology targeting oral, intranasal and IV routes. more info

FDA Approves Abuse Deterrent IR Oxycodone

The FDA has approved RoxyBond abuse-deterrent oxycodone hydrochloride tablets (RoxyBond, Inspirion) for the management of pain severe enough to require an opioid analgesic, and when alternative treatments are inadequate. more info

How to Safely Dispose of Leftover Painkillers and Other Medications

How to Safely Dispose of Leftover Painkillers and Other Medications more info